Erin Taylor
Family · Harvey, LANPI 1457927212
Payments from drug & device makers
Across 72 payments — averaging $28.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$554
- AstraZeneca$306
- Novo Nordisk$270
- Inspire Medical Systems, Inc.$135
- Madrigal Pharmaceuticals$123
- AbbVie$122
- plus $517 from 10 others
What the payments were for
- Food & beverage$2,029100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 24 | $554 |
| AstraZeneca | 6 | $306 |
| Novo Nordisk | 13 | $270 |
| Inspire Medical Systems, Inc. | 2 | $135 |
| Madrigal Pharmaceuticals | 1 | $123 |
| AbbVie | 6 | $122 |
| Johnson & Johnson | 1 | $115 |
| Sanofi | 1 | $90 |
| Boehringer Ingelheim | 4 | $72 |
| Bayer | 3 | $55 |
| Astellas Pharma US Inc | 3 | $51 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Dexcom, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,029 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levocetirizine Dihydrochloride | 40 | $488 |
| Rosuvastatin Calcium | 26 | $266 |
| Pantoprazole Sodium | 15 | $261 |
| Fluticasone Propionate | 27 | $258 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 20 | $210 |
| Atorvastatin Calcium | 17 | $171 |
| Gabapentin | 15 | $123 |
| Losartan Potassium | 12 | $94 |
| Pravastatin Sodium | 17 | $87 |
| Alendronate Sodium | 18 | $82 |
| Amlodipine Besylate | 20 | $61 |
| Azithromycin | 13 | $46 |
| Trazodone Hcl | 11 | $28 |
Paid to pharmacies, not to this prescriber.
Other family in Harvey
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.